Last reviewed · How we verify
YM150
YM150 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
YM150 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Type 2 diabetes.
At a glance
| Generic name | YM150 |
|---|---|
| Also known as | darexaban |
| Sponsor | Astellas Pharma Inc |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, YM150 reduces glucose reabsorption in the kidneys, leading to a decrease in blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
- A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery (PHASE2, PHASE3)
- Study Evaluating Safety, Tolerability and Efficacy of YM150 in Subjects With Acute Coronary Syndromes (PHASE2)
- To Evaluate if Multiple Doses of Ketoconazole Change the Blood Concentration of YM150 (Darexaban) (PHASE1)
- A Study to Find Out How YM150 is Absorbed Into and Eliminated From the Body in Healthy Male Subjects (PHASE1)
- A Study to Evaluate the Safety and Tolerability of YM150 in Healthy Caucasian and Japanese Male and Female Subjects, and to Assess the Effect That Gender May Have on Its Actions in the Body (PHASE1)
- To Evaluate Whether Naproxen and Darexaban (YM150) Interact in Their Effects (PHASE1)
- To Evaluate if Multiple Doses of Rifampicin Change the Blood Concentration of YM150 (Darexaban) (PHASE1)
- A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement Surgery (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YM150 CI brief — competitive landscape report
- YM150 updates RSS · CI watch RSS
- Astellas Pharma Inc portfolio CI